Paper ยท 31398337
Tumor Microbiome Diversity and Composition Influence Pancreatic Cancer Outcomes.
Riquelme E and 30 others. Cell, 2019. Cited by 1,293 papers, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. Tumor Microbiome Diversity and Composition Influence Pancreatic Cancer Outcomes. Papers, record 31398337. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/31398337
On this page
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Publication types
- Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't
- PubMed
Topics20
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Carcinoma, Pancreatic Ductal | Major topic |
| Gastrointestinal Microbiome | Major topic |
| Pancreatic Neoplasms | Major topic |
| Adult | |
| Aged | |
| Animals | |
| Bacteria | |
| Cell Line, Tumor | |
| Cohort Studies | |
| Fecal Microbiota Transplantation | |
| Feces | |
| Female | |
| Humans | |
| Male | |
| Mice | |
| Mice, Inbred C57BL | |
| Middle Aged | |
| RNA, Ribosomal, 16S | |
| Sequence Analysis, RNA | |
| Survival Rate |
Source PubMed
Grants4
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by | Source |
|---|---|---|---|---|---|
| K08 CA218690 | NCI NIH HHS | United States | K08CA218690 | PubMed | NIH RePORTER |
| K12 CA088084 | NCI NIH HHS | United States | K12CA088084 | PubMed | NIH RePORTER |
| P30 CA016672 | NCI NIH HHS | United States | P30CA016672 | PubMed | NIH RePORTER |
| R25 CA056452 | NCI NIH HHS | United States | R25CA056452 | PubMed | NIH RePORTER |
Trials4
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
| Trial | Title | The trial lists it as | Named in the paper's record | Source |
|---|---|---|---|---|
| NCT04787991 | Exploratory Platform Trial to Evaluate Immunotherapy Combinations With Chemotherapy for the Treatment of Patients With Previously Untreated Metastatic Pancreatic Adenocarcinoma | Background | ClinicalTrials.gov | |
| NCT07818421 | Intratumoral Microbiota and Immune Microenvironment in Prostate Cancer | Results | ClinicalTrials.gov | |
| NCT07845565 | FMT Plus SHR-1701 With Nab-Paclitaxel/Gemcitabine as First-Line Treatment for Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma | Background | ClinicalTrials.gov | |
| NCT07854977 | Fecal Microbiota Transplantation Combined With NALIRIFOX Plus Serplulimab as First-line Treatment for Advanced or Metastatic Pancreatic Ductal Adenocarcinoma. | Background | ClinicalTrials.gov |
Comments and corrections3
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
| Kind | PMID | Title | In Papers | Source |
|---|---|---|---|---|
| Comment in | 31,471,581 | Tumour microbiome defines outcomes. | https://conductscience.org/library/papers/31471581 | PubMed |
| Comment in | 31,477,872 | Tumour microbiome defines outcomes. | https://conductscience.org/library/papers/31477872 | PubMed |
| Comment in | 31,530,941 | Microbes as biomarkers and targets in pancreatic cancer. | https://conductscience.org/library/papers/31530941 | PubMed |
References56
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 29,567,829 | The Pancreatic Cancer Microbiome Promotes Oncogenesis by Induction of Innate and Adaptive Immune Suppression. | Cancer Discov | 2018 | https://conductscience.org/library/papers/29567829 | PubMed |
| 2 | 29,214,046 | High-resolution bacterial 16S rRNA gene profile meta-analysis and biofilm status reveal common colorectal cancer consortia. | NPJ Biofilms Microbiomes | 2017 | https://conductscience.org/library/papers/29214046 | PubMed |
| 3 | 29,051,489 | Genomic landscape associated with potential response to anti-CTLA-4 treatment in cancers. | Nat Commun | 2017 | https://conductscience.org/library/papers/29051489 | PubMed |
| 4 | 29,132,146 | Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer. | Nature | 2017 | https://conductscience.org/library/papers/29132146 | PubMed |
| 5 | 23,842,501 | Treg induction by a rationally selected mixture of Clostridia strains from the human microbiota. | Nature | 2013 | https://conductscience.org/library/papers/23842501 | PubMed |
| 6 | 20,709,691 | Search and clustering orders of magnitude faster than BLAST. | Bioinformatics | 2010 | https://conductscience.org/library/papers/20709691 | PubMed |
| 7 | 20,979,621 | Differential expression analysis for sequence count data. | Genome Biol | 2010 | https://conductscience.org/library/papers/20979621 | PubMed |
| 8 | 21,700,674 | UCHIME improves sensitivity and speed of chimera detection. | Bioinformatics | 2011 | https://conductscience.org/library/papers/21700674 | PubMed |
| 9 | 22,699,609 | Structure, function and diversity of the healthy human microbiome. | Nature | 2012 | https://conductscience.org/library/papers/22699609 | PubMed |
| 10 | 27,253,694 | Cancer treatment and survivorship statistics, 2016. | CA Cancer J Clin | 2016 | https://conductscience.org/library/papers/27253694 | PubMed |
1 to 10 of 56
See all 56 referencesCited by999
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 1,293 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42,979,040 | Naringenin in pancreatic cancer: emerging evidence on the tumor immune-stromal microenvironment, immunometabolic reprogramming, microbiota-host crosstalk, and therapeutic resistance. | Front Immunol | 2026 | https://conductscience.org/library/papers/42979040 | PubMed |
| 42,967,594 | The microbiome and brain metastasis in non-small cell lung cancer: A graded appraisal and a framework for prevention-oriented research. | Clin Transl Med | 2026 | https://conductscience.org/library/papers/42967594 | PubMed |
| 42,957,707 | Genome mining of the tumor microbiome reveals biosynthetic diversity and potential pathology-modulating metabolites. | Nat Commun | 2026 | https://conductscience.org/library/papers/42957707 | PubMed |
| 42,957,626 | Autophagy and intratumoral bacteria abundance influence the prognosis of patients with pancreatic carcinoma. | Cell Death Dis | 2026 | https://conductscience.org/library/papers/42957626 | PubMed |
| 42,950,024 | A systematic pan-cancer analysis of intratumoral microbiota-derived epitopes to inform cancer immunotherapy and prevention. | Sci Adv | 2026 | https://conductscience.org/library/papers/42950024 | PubMed |
| 42,941,196 | Gut Microbiome Compositional and Functional Signatures Associated with Chemotherapy Response in Pancreatic Ductal Adenocarcinoma: An Exploratory Cohort Study. | Metabolites | 2026 | https://conductscience.org/library/papers/42941196 | PubMed |
| 42,935,951 | Microbial-derived metabolites in cancer: evidence boundaries, immune mechanisms and translational pathways. | Front Immunol | 2026 | https://conductscience.org/library/papers/42935951 | PubMed |
| 42,930,196 | Canadian National Pancreas Conference 2025: Recent Advances in Patient-Centred Management of Pancreatic Cancer. | Curr Oncol | 2026 | https://conductscience.org/library/papers/42930196 | PubMed |
| 42,909,229 | Gut mycobiome dysbiosis in digestive system cancers: immune remodeling and translational implications. | Front Cell Infect Microbiol | 2026 | https://conductscience.org/library/papers/42909229 | PubMed |
| 42,903,607 | The intratumoral microbiome in breast cancer: an actionable component of the tumor immune microenvironment. | Front Immunol | 2026 | https://conductscience.org/library/papers/42903607 | PubMed |
1 to 10 of 999
See all 999 cited byGenes7
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| CD274 | 29,126 | PubTator's text mining | https://conductscience.org/library/genes/29126 | NCBI Gene |
| CEACAM8 | 1,088 | PubTator's text mining | https://conductscience.org/library/genes/1088 | NCBI Gene |
| CTLA4 | 1,493 | PubTator's text mining | https://conductscience.org/library/genes/1493 | NCBI Gene |
| FOXP3 | 50,943 | PubTator's text mining | https://conductscience.org/library/genes/50943 | NCBI Gene |
| GZMB | 3,002 | PubTator's text mining | https://conductscience.org/library/genes/3002 | NCBI Gene |
| KIT | 3,815 | PubTator's text mining | https://conductscience.org/library/genes/3815 | NCBI Gene |
| PDX1 | 3,651 | PubTator's text mining | https://conductscience.org/library/genes/3651 | NCBI Gene |
Drugs0
The drugs whose trials, in the Pipelines release, list the paper.
None in this release.
Data0
The data bank entries PubMed's record names. Trial numbers are under Trials.
None in this release.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/31398337
GET https://conductscience.org/api/papers/v1/31398337/authors?page=2